sb 203580 has been researched along with milrinone in 2 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (milrinone) | Trials (milrinone) | Recent Studies (post-2010) (milrinone) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 1,605 | 235 | 452 |
Protein | Taxonomy | sb 203580 (IC50) | milrinone (IC50) |
---|---|---|---|
Phosphodiesterase | Bos taurus (cattle) | 1 | |
cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.3 | |
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.3 | |
cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.52 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.7 | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 6 | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 6 | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 6 | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.15 | |
cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 1.8674 | |
cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 1.8177 | |
cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | 5 | |
Phosphodiesterase | Sus scrofa (pig) | 0.843 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J | 1 |
2 other study(ies) available for sb 203580 and milrinone
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Enzyme Inhibitors; Flavonoids; Hemodynamics; Imidazoles; Indoles; Isoquinolines; Maleimides; Milrinone; Mitogen-Activated Protein Kinases; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridines; Pyridones; Sulfonamides; Ventricular Fibrillation | 2001 |